Inflammation triggers pain because damaged or infected tissue releases a flood of chemical signals that directly activate nerve endings and, critically, make those nerve endings far more sensitive than normal. The result is that stimuli you would barely notice under healthy conditions — light pressure, a small change in temperature — suddenly register as painful. This heightened sensitivity is not a malfunction. It is a carefully orchestrated biological alarm system, but the machinery behind it is surprisingly layered, involving immune cells, specialized ion channels, growth factors, spinal cord rewiring, and even brain-resident support cells.
Why Inflammation Hurts at All
From an evolutionary standpoint, pain during inflammation exists to protect you. People born without the ability to feel pain accumulate severe tissue damage, especially to their skin and joints, and tend to die young. The damage comes not just from external injuries but from something subtler: without pain signals, they lack the motivation for the small, unconscious movements that protect joints and skin from sustained pressure and restricted blood supply.
Pain also promotes healing by discouraging you from using an injured area. A sprained ankle that hurts when you walk on it forces you to rest, giving the tissue time to repair. In this sense, inflammatory pain is a behavioral leash. It limits movement and disruption at the injury site.
The Chemical Soup at the Injury Site
When tissue is damaged or invaded by pathogens, cells in and around the injury release a cocktail of molecules that collectively kick-start pain signaling. Several of these molecules deserve attention because they each act on nerve endings in distinct ways.
One of the most immediate triggers is a drop in tissue pH. Damaged cells leak their contents, and the local environment becomes more acidic. This acidity alone is enough to activate pain-sensing nerve fibers. A related trigger is adenosine triphosphate, or ATP, a molecule present in every cell but concentrated in muscle. When cells rupture from trauma or inflammation, ATP spills into the surrounding tissue and acts as a direct pain stimulus.
Prostaglandins are another major player. Enzymes called cyclooxygenases ramp up production of prostaglandins at an inflamed site. One prostaglandin in particular, prostaglandin E2, has been studied extensively. In mice engineered to lack the receptor for it, pain responses in inflammatory tests dropped by roughly half — a reduction that matched what happens when you block prostaglandin production entirely with a cyclooxygenase inhibitor.
Then there are the cytokines, signaling proteins released largely by immune cells. Two of the most studied are tumor necrosis factor alpha and interleukin-1 beta, both of which directly alter the sensitivity of pain-sensing neurons. When applied even in tiny amounts to nerve tissue in the lab, these cytokines increase the firing rate of nerve fibers and make them respond more vigorously to mechanical pressure.
How Nerve Endings Become Hypersensitive
The chemical signals described above do not just trigger pain in the moment. They also change the way nerve endings behave going forward, a process called peripheral sensitization. Normally, pain-sensing nerve endings — nociceptors — have a certain threshold: it takes a specific intensity of heat, pressure, or chemical irritation to make them fire. During inflammation, that threshold drops, sometimes dramatically.
One way this happens involves prostaglandin E2 acting on internal signaling pathways within the nerve cell. Under normal conditions, prostaglandin E2 uses one particular signaling route to amplify pain signals. After inflammation sets in, the nerve cells switch to using an additional pathway on top of the original one, roughly doubling the amplification available.
Another route to hypersensitivity runs through nerve growth factor, or NGF. During inflammation, NGF levels rise sharply in the affected tissue. NGF then acts on nociceptors to ramp up the production of ion channels and receptors that make the nerve ending more excitable. One downstream effect is increased expression of acid-sensing ion channels, which respond to the acidic conditions at the injury site. The combination means the nerve endings are both sitting in more acid and equipped with more acid detectors — a recipe for amplified pain.
Blocking NGF signaling has been shown to reduce pain-related behavior across a range of inflammatory conditions in animal models, from arthritis to bone cancer pain, confirming how central NGF is to the inflammatory pain experience.
Ion Channels That Open the Gate
Ion channels are the molecular doors that, when opened, allow charged particles to flow into a nerve cell and trigger an electrical signal. Several families of these channels play starring roles in inflammatory pain.
TRPA1 is one that has attracted substantial research attention. Found on the peripheral endings of nociceptors, TRPA1 channels are activated by inflammatory agents released from both nerve cells and non-neuronal cells at the injury site. Once activated, they trigger the nerve cell to fire and also promote the release of inflammatory neuropeptides from the nerve ending itself, which feeds back into the inflammatory process.
Voltage-gated sodium channels, particularly three subtypes found almost exclusively on pain-sensing neurons, are equally important. During chronic inflammation, the expression of all three subtypes increases in the nerve cells that supply the inflamed area. In experiments modeling joint inflammation, all three showed elevated levels for weeks after the initial insult, coinciding with sustained pain behaviors. Because these channels are concentrated in peripheral pain neurons rather than throughout the nervous system, they have become attractive targets for new pain medications. A drug that blocks all three has shown broad pain-relieving effects in preclinical models with favorable safety margins, precisely because it would not disrupt signaling elsewhere in the body.
The Immune System as Pain Amplifier
Pain during inflammation is not simply a matter of nerve endings detecting damage. The immune system actively contributes to making you hurt more. After an injury, resident immune cells at the site become activated, and additional immune cells are recruited from the bloodstream. These cells do not just fight infection — they also release the inflammatory mediators that sensitize nociceptors.
The result is an integrated network. Immune cells release cytokines and prostaglandins, which act on nerve endings. Those nerve endings, in turn, release neuropeptides like substance P and calcitonin gene-related peptide back into the tissue, which cause blood vessels to dilate, fluid to leak from capillaries, and mast cells to dump even more inflammatory chemicals. This loop, sometimes called neurogenic inflammation, means the nervous system and the immune system egg each other on, amplifying both the immune response and the pain signal simultaneously.
When Pain Gets Amplified in the Spinal Cord
Everything discussed so far happens at or near the injury. But if inflammatory pain were only a local event, it would not explain some of its more perplexing features — like why the skin around an inflamed joint becomes tender to touch even though it is not injured, or why inflammatory pain sometimes persists long after the original tissue damage has healed.
The explanation lies in central sensitization, a set of changes in the spinal cord and brain that amplify pain signals. When nociceptors bombard the spinal cord with a sustained barrage of input, the spinal neurons that relay pain signals to the brain become hyperexcitable. Their thresholds drop, much like the peripheral nerve endings described earlier, but now the amplification is happening upstream in the central nervous system.
One mechanism behind this involves a signaling molecule called CCL2. In the spinal cord, CCL2 acts on receptors in excitatory neurons and enhances the activity of NMDA receptors, which are critical for learning and memory-like changes in synaptic strength. Blocking the CCL2 receptor in animal models reversed both the enhanced synaptic activity and the pain behavior caused by inflammation.
Glial cells in the spinal cord also play a role. Microglia, which act as the central nervous system’s resident immune cells, amplify neuronal activity in the spinal cord during sustained inflammatory pain. In a separate line of research, astrocytes — another type of glial cell — were found to contribute specifically to inflammatory pain sensitization (as opposed to nerve-injury pain, which relies more heavily on microglia). Blocking astrocyte activity in the spinal cord reduced the amplified neuronal responses in animals with inflammatory pain but not in those with nerve injuries, suggesting these two types of chronic pain run through partially distinct pathways.
Why Gut Pain Feels Different from a Twisted Ankle
Not all inflammatory pain behaves the same way. Pain originating from internal organs — visceral pain — differs from pain in muscles, joints, and skin in several important respects. Visceral pain tends to be diffuse and hard to localize, while somatic pain is usually sharp and well-defined. The neurobiological differences run deeper than just how the pain feels.
The nerve fibers serving internal organs are influenced heavily by the local environment — the muscular contractions, secretions, and chemical conditions of the gut wall or bladder, for instance. Sensitization of visceral pain pathways can involve different molecular mechanisms, including the movement of certain receptors from the interior of nerve cells to their surface, a process not as prominent in somatic pain.
One striking difference involves the sodium channel NaV1.7, which is critical for somatic inflammatory pain. In animal studies, NaV1.7 turned out to be required for sensing inflammatory and acute somatic pain but not for visceral pain signaling at all. This matters practically: a drug designed to block NaV1.7 might relieve a sore knee but do little for the cramping pain of inflammatory bowel disease. The finding underscores that “inflammatory pain” is not a single entity and that different tissues use different wiring to generate pain signals.
Sex Differences in Inflammatory Pain Processing
Men and women appear to process inflammatory pain through partially different immune mechanisms, at least based on animal research. In males, the transition from acute to chronic pain states relies more heavily on the innate immune system — neutrophils arriving at the injury site, monocytes infiltrating the central nervous system, and microglial cells in the spinal cord communicating with neurons through pathways involving specific purinergic receptors and signaling molecules like brain-derived neurotrophic factor.
In females, sustained pain states depend more on the adaptive immune system, particularly T cells. In one experiment, injection of a protein that triggers T-cell migration caused those cells to travel to the spinal cord and produce pain behavior in female mice but not in males, where the T cells stayed near the injection site.
These differences have real implications for treatment. A drug targeting microglial activation might work well for one sex but poorly for the other. Clinical pain research has historically been conducted predominantly in males (both human and animal), which means a significant portion of what we “know” about inflammatory pain mechanisms may apply more strongly to male physiology. The field is catching up, but it is worth remembering that your personal experience of inflammatory pain may not map neatly onto the textbook description.
How the Body Turns Inflammatory Pain Off
Inflammation is not supposed to last forever, and neither is the pain that comes with it. The body produces its own family of molecules, broadly called specialized pro-resolving mediators, that actively shut down both the inflammatory response and the pain it produces. Two of the best-studied members, resolvin E1 and resolvin D1, reduce inflammatory and postoperative pain in animal models by acting on both immune cells and neurons.
These molecules work through several routes at once. They normalize levels of the inflammatory mediators that sensitize nerve endings, they act directly on TRP ion channels to reduce their excitability, and they dampen exaggerated signaling in the spinal cord. In animal studies, knocking out the receptors for these resolvins impairs the normal resolution of pain — the pain lingers even after the inflammation has subsided. This suggests that chronic inflammatory pain may not always be about too much inflammation. It can also be about too little resolution.
When Background Inflammation Primes You for More Pain
You do not need a discrete injury to have inflammatory pain. Conditions that produce low-grade, chronic inflammation can prime the entire pain system to overreact. Obesity is one of the clearest examples. Excess fat tissue actively secretes inflammatory cytokines — including the same TNF-alpha, IL-1 beta, and IL-6 that sensitize nerve endings during acute injury. In mice fed a high-fat diet, elevated levels of these cytokines appeared in both the bloodstream and in the nerve tissue itself, while anti-inflammatory IL-10 dropped. Gene expression of the pro-inflammatory cytokines also increased in the nerve ganglia, providing a ready-made environment for exaggerated pain responses to routine stimuli.
The combined effect is a three-level sensitization: inflammatory cytokines act on peripheral nerve endings to lower their activation thresholds, they circulate in the blood to reach the spinal cord and brain, and they promote the kind of central sensitization described earlier. People with obesity often report more pain from conditions like osteoarthritis than their joint damage alone would predict, and this systemic inflammatory priming is one reason why.
Chronic psychological stress operates through a parallel route. Prolonged stress can disrupt cortisol regulation, and when cortisol stops functioning properly as an anti-inflammatory brake, systemic inflammation increases. Exaggerated stress responses — such as catastrophizing about pain — can themselves amplify cortisol secretion and reinforce fear-based memories of pain, creating a cycle where stress fuels inflammation, inflammation fuels pain, and pain fuels more stress.
How Common Painkillers Fit into This Picture
Understanding the molecular cascade of inflammatory pain makes it clearer why certain drugs work and where they fall short. Nonsteroidal anti-inflammatory drugs — ibuprofen, naproxen, aspirin — work by blocking cyclooxygenase enzymes, which cuts off the production of prostaglandins at the injury site. Since prostaglandins are responsible for a large portion of peripheral sensitization, this reduces both pain and swelling.
But cyclooxygenase inhibition does nothing about the cytokines, the NGF, the acid, the ATP, or the central sensitization that may already be underway. That is why NSAIDs work well for mild to moderate inflammatory pain but have limits when inflammation is severe or has been going on long enough for the spinal cord to get involved. Corticosteroids, which suppress a broader range of the inflammatory response, can reach further into the cascade but come with their own downsides for long-term use.
The more specific targets — blocking NGF, developing selective sodium channel blockers, or harnessing the body’s own resolvin pathways — represent a newer wave of approaches that aim to interrupt the pain cascade at different, potentially more precise, points. None of these has yet replaced the standard toolkit for most patients, but they reflect a growing understanding that inflammatory pain is not one process but many, and that the best intervention depends on which part of the cascade is doing the most damage.
The Neurogenic Feedback Loop
One of the more counterintuitive aspects of inflammatory pain is that the nervous system does not just passively receive information from the inflamed tissue — it actively makes the inflammation worse. When nociceptors are activated, they release neuropeptides from their own endings back into the surrounding tissue. Substance P and calcitonin gene-related peptide cause blood vessels to widen, fluid to leak out of capillaries, and immune cells like mast cells to release their own stockpile of inflammatory chemicals.
This is neurogenic inflammation, and it is thought to play a role in conditions ranging from migraine to asthma. In migraine specifically, the release of these neuropeptides from the trigeminal nerve system produces vasodilation, plasma leakage, and swelling that sustain and intensify the headache. TRPA1 channels, the same ion channels that transduce noxious stimuli at the nerve ending, also drive the release of these inflammatory neuropeptides, making them both a sensor and an amplifier of the inflammatory process.
The practical consequence is that inflammatory pain can be somewhat self-sustaining. The nerve endings that detect inflammation also contribute to it, creating a positive feedback loop that does not switch off easily once it gets going. Breaking this loop is part of what effective pain treatment needs to accomplish, and it is one reason why early intervention — treating inflammation before the feedback cycle fully ramps up — tends to work better than waiting.